United States · legal reference

State Policy Map

A cautious, source-led way to separate federal scheduling, state law, legislative activity, and documented research involving ibogaine in the United States.

Last updated October 6, 2026 · legal status can change through legislation, rulemaking, and court action.

Close detail suggesting the careful review of ibogaine policy records

How to use this page

Read the legal baseline before the headline.

Ibogaine is listed by the U.S. Drug Enforcement Administration as a Schedule I controlled substance under federal law. The DEA’s scheduling framework is therefore the starting point for every jurisdiction, but it is not the only record worth checking.

States may mirror federal scheduling, adopt their own controlled-substance provisions, consider study or funding measures, or leave particular questions to existing statutory language. This map is designed to sit beside the broader U.S. ibogaine policy overview and the site’s legal and safety context, not to substitute for legal or medical advice.

For plain-language background on the compound’s history and classification, the ibogaine reference entry can orient a reader; the controlling materials remain statutes, official actions, and agency records.

All states + District of Columbia

A jurisdiction-by-jurisdiction research frame.

51 records, one consistent lens

Each jurisdiction should be reviewed for statutory status, dated legislative or executive action, documented research or pilot activity, and unresolved legal questions. A state’s silence is not an exception; a proposal is not enacted law; and research authorization is not routine lawful availability.

ALAKAZARCACO CTDEDCFLGAHI IDILINIAKSKY LAMEMDMAMIMN MSMOMTNENVNH NJNMNYNCNDOH OKORPARISCSD TNTXUTVTVAWA WVWIWY

Documents and visual detail supporting a careful review of state-by-state policy

Evidence order

What counts as a state record.

Start with the enacted code and the state’s official legislative history. Then check dated executive actions, appropriations, agency rules, hearing materials, and public court filings. Federal records remain relevant when a state measure references research, controlled substances, or investigational pathways.

Use bill text and final status rather than bill titles or summaries alone.
Record public funding only when an appropriation, budget, or official sponsor identifies an amount.
For study activity, verify a protocol or recruitment record through the federal ClinicalTrials.gov registry and read the study status in context.
Keep uncertainty visible when an agency interpretation, pending measure, or litigation leaves a question unresolved.

Comparison fields

Four fields make the comparison usable.

These fields keep state entries comparable without implying that legislative interest or research activity changes the underlying legal baseline.

01 / STATUS

Current statutory text

Note whether ibogaine appears in a state schedule, whether related language is incorporated by reference, and whether the code identifies any limited exception.

02 / ACTION

Dated official activity

Capture introduced bills, enacted measures, executive orders, agency notices, appropriations, and the source location for each dated action.

03 / RESEARCH

Documented programs

Identify the sponsoring institution, public record, protocol or registry listing, and funding amount only when those details are publicly documented.

Boundary conditions

Keep the unanswered questions attached to the record.

Legal classification, proposed policy, and research oversight are different categories—and should not be collapsed into a claim of availability.

Outstanding questions may concern the effect of a newly passed measure, agency implementation, the scope of a research authorization, a conflict between state and federal rules, or a pending court interpretation. The official congressional record system is useful for federal legislative context, while state legislative portals remain necessary for state-specific action.

Readers comparing potential treatment claims should also consult the site’s discussion of reported ibogaine therapy benefits with caution: a policy map does not establish safety, efficacy, or lawful medical access. For substance-use claims, the separate material on ibogaine for addiction treatment should likewise be read as background rather than a legal determination.

Quick reference

Questions this map is built to clarify.

Does federal scheduling settle every state-level question?

No. Federal scheduling is an important baseline, while state statutes, controlled-substance schedules, enforcement authority, research permissions, and enacted state measures can create separate questions that require primary-source review.

Does research activity mean ibogaine is available as routine care?

No. A study listing, pilot discussion, or research program is not the same thing as a generally lawful treatment pathway. Trial protocol, enrollment, oversight, and jurisdiction-specific law matter. Information about treatment centers in Mexico concerns a different jurisdiction and does not answer a U.S. state-law question.

What kinds of sources support this map?

The map prioritizes state statutes, legislative history, appropriations bills, executive actions, federal records, ClinicalTrials.gov entries, and court filings where available. Broader discussions of an ibogaine alternative, ibogaine and Alzheimer’s, or ibogaine and dementia do not replace those source types.

Method before conclusion

Use primary sources to test any state-level claim.

A careful reading distinguishes enacted policy from a proposal, documented research from marketing, and a legal question from a medical recommendation.

Review research resources